Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
Department of Biomedicine, University of Bergen, Bergen, Norway.
Elife. 2019 May 20;8:e41711. doi: 10.7554/eLife.41711.
Regulated exocytosis establishes a narrow fusion pore as initial aqueous connection to the extracellular space, through which small transmitter molecules such as ATP can exit. Co-release of polypeptides and hormones like insulin requires further expansion of the pore. There is evidence that pore expansion is regulated and can fail in diabetes and neurodegenerative disease. Here, we report that the cAMP-sensor Epac2 (Rap-GEF4) controls fusion pore behavior by acutely recruiting two pore-restricting proteins, amisyn and dynamin-1, to the exocytosis site in insulin-secreting beta-cells. cAMP elevation restricts and slows fusion pore expansion and peptide release, but not when Epac2 is inactivated pharmacologically or in Epac2 () mice. Consistently, overexpression of Epac2 impedes pore expansion. Widely used antidiabetic drugs (GLP-1 receptor agonists and sulfonylureas) activate this pathway and thereby paradoxically restrict hormone release. We conclude that Epac2/cAMP controls fusion pore expansion and thus the balance of hormone and transmitter release during insulin granule exocytosis.
受调控的胞吐作用形成狭窄的融合孔,作为与细胞外空间初始的水相连接,通过该孔小分子递质如 ATP 可以排出。多肽和激素如胰岛素的共同释放需要进一步扩大孔道。有证据表明,孔道的扩张是受调控的,在糖尿病和神经退行性疾病中可能会发生故障。在这里,我们报告 cAMP 感受器 Epac2(Rap-GEF4)通过将两种限制孔道的蛋白,即 amisin 和 dynamin-1,急性募集到胰岛素分泌β细胞的胞吐部位来控制融合孔的行为。cAMP 的升高限制并减缓了融合孔的扩张和肽类的释放,但当 Epac2 被药理学方法失活或在 Epac2()小鼠中则不会。一致地,Epac2 的过表达会阻碍孔道的扩张。广泛使用的抗糖尿病药物(GLP-1 受体激动剂和磺酰脲类药物)激活该途径,从而矛盾地限制激素的释放。我们得出结论,Epac2/cAMP 控制融合孔的扩张,从而控制胰岛素颗粒胞吐过程中激素和递质释放的平衡。